Danish researchers conducted a study looking at the potential association of rosacea
and the risk for glioma. In glioma, there is an upregulation of specific matrix metalloproteinases.
Similarly, in rosacea, it is hypothesized that increased matrix metalloproteinase
activity is involved. The researchers used data from a nationwide database to conduct
a cohort study, starting in 1997 and following the patients until 2011. The study
included 5 484 910 individuals who did not have rosacea or glioma at the start of
the study, of whom 68 372 were diagnosed with rosacea during the duration of the study.
For the entire population, 21 118 developed glioma during the study. Of these patients,
20 934 were in the reference population without rosacea, and 184 were in the group
with rosacea. The incidence rate of glioma per 10 000 person-years was 3.34 (95% CI,
3.30–3.39) in the reference population and 4.99 (4.32–5.76) in the rosacea population.
When the rate was adjusted for age, sex, and socioeconomic status, the adjusted incident
rate ratio was 1.36 (1.18–1.58) for glioma in the rosacea population, and when the
results were analyzed for those patients who had a diagnosis of rosacea confirmed
by a hospital dermatologist, the adjusted incidence rate ratio was 1.83 (1.16–2.86).
The authors concluded that rosacea was associated with a significantly increased risk
for glioma compared with the general population, possibly because of a shared underlying
pathogenic mechanism related to increased matrix metalloproteinase levels.
To read this article in full you will need to make a payment